Characterizing factors associated with differences in FGF19 blood levels and synthesis in patients with primary bile acid diarrhea

American Journal of Gastroenterology

Volumn 111, Issue 3, 2016, Pages 423-432

  Johnston, Ian M ^a   Nolan, Jonathan D ^a   Pattni, Sanjeev S ^a   Appleby, Richard N ^a   Zhang, Justine H ^a   Kennie, Sarah L ^a   Madhan, Gaganjit K ^a   Jameie Oskooei, Sina ^a   Pathmasrirengam, Shivani ^a   Lin, Jeremy ^a   Hong, Albert ^a   Dixon, Peter H ^b,c   Williamson, Catherine ^b,c   Walters, Julian R F ^a  

^a IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c GUY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BILE ACID; BINDING PROTEIN; CHENODEOXYCHOLIC ACID; FIBROBLAST GROWTH FACTOR 19; FIBROBLAST GROWTH FACTOR RECEPTOR 4; LIPID; TAUROSELCHOLIC ACID SE 75; 23-SELENO-25-HOMOTAUROCHOLIC ACID; CELL RECEPTOR; FARNESOID X-ACTIVATED RECEPTOR; FGF19 PROTEIN, HUMAN; FGFR4 PROTEIN, HUMAN; FIBROBLAST GROWTH FACTOR; KLB PROTEIN, HUMAN; MEMBRANE PROTEIN; SELENIUM; TAUROCHOLIC ACID; TRIACYLGLYCEROL;

ARTICLE; BILE ACID SYNTHESIS; CONTROLLED STUDY; DIARRHEA; DIET RESTRICTION; DRUG RETENTION; GASTROINTESTINAL BIOPSY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; HYPERTRIGLYCERIDEMIA; IDIOPATHIC DISEASE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; PRIMARY BILE ACID DIARRHEA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; ADULT; ANALOGS AND DERIVATIVES; BIOSYNTHESIS; BLOOD; BODY MASS; FEMALE; GENETICS; ILEUM; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; STATISTICS;

ADULT; BILE ACIDS AND SALTS; BODY MASS INDEX; DIARRHEA; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; ILEUM; MALE; MEMBRANE PROTEINS; MIDDLE AGED; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 4; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SELENIUM RADIOISOTOPES; STATISTICS AS TOPIC; TAUROCHOLIC ACID; TRIGLYCERIDES;

EID: 84957824306     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2015.424     Document Type: Article

References (43)

1. Walters JR. Defining primary bile acid diarrhea: making the diagnosis and recognizing the disorder. Expert Rev Gastroenterol Hepatol 2010; 4: 561-7.
2. Wedlake L, A'Hern R, Thomas K, et al. Systematic review: the prevalence of idiopathic bile acid malabsorption (I-BAM) as diagnosed by SeHCAT scanning in patients with diarrhoea-predominant irritable bowel syndrome (IBS). Aliment Pharmacol Ther 2009; 30: 707-17.
3. Bajor A, Tornblom H, Rudling M, et al. Increased colonic bile acid exposure: a relevant factor for symptoms and treatment in IBS. Gut 2015; 64: 84-92.
4. Camilleri M, Busciglio I, Acosta A, et al. Effect of increased bile acid synthesis or fecal excretion in irritable bowel syndrome-diarrhea. Am J Gastroenterol 2014; 109: 1621-30.
5. Gracie DJ, Kane JS, Mumtaz S, et al. Prevalence of, and predictors of, bile acid malabsorption in outpatients with chronic diarrhea. Neurogastroenterol Motil 2012; 24: 983-e538.
6. Kurien M, Evans KE, Leeds JS, et al. Bile acid malabsorption: an underinvestigated differential diagnosis in patients presenting with diarrhea predominant irritable bowel syndrome type symptoms. Scand J Gastroenterol 2011; 46: 818-22.
7. Slattery SA, Niaz O, Aziz Q, et al. Systematic review with meta-analysis: the prevalence of bile acid malabsorption in the irritable bowel syndrome with diarrhoea. Aliment Pharmacol Ther 2015; 42: 3-11.
8. Brydon WG, Nyhlin H, Eastwood MA, et al. Serum 7 alpha-hydroxy-4-cholesten-3-one and selenohomocholyltaurine (SeHCAT) whole body retention in the assessment of bile acid induced diarrhoea. Eur J Gastroenterol Hepatol 1996; 8: 117-23.
9. Vijayvargiya P, Camilleri M, Shin A, et al. Methods for diagnosis of bile acid malabsorption in clinical practice. Clin Gastroenterol Hepatol 2013; 11: 1232-9.
10. Walters JR. Bile acid diarrhoea and FGF19: new views on diagnosis, pathogenesis and therapy. Nat Rev Gastroenterol Hepatol 2014; 11: 426-34.
11. Inagaki T, Choi M, Moschetta A, et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab 2005; 2: 217-25.
12. Zhang JH, Nolan JD, Kennie SL, et al. Potent stimulation of fibroblast growth factor 19 expression in the human ileum by bile acids. Am J Physiol Gastrointest Liver Physiol 2013; 304: G940-8.
13. Lundasen T, Galman C, Angelin B, et al. Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man. J Intern Med 2006; 260: 530-6.
14. Galman C, Angelin B, Rudling M. Pronounced variation in bile acid synthesis in humans is related to gender, hypertriglyceridaemia and circulating levels of fibroblast growth factor 19. J Intern Med 2011; 270: 580-8.
15. Wong BS, Camilleri M, Carlson P, et al. Increased bile acid biosynthesis is associated with irritable bowel syndrome with diarrhea. Clin Gastroenterol Hepatol 2012; 10: 1009-15.
16. Pattni SS, Brydon WG, Dew T, et al. Fibroblast growth factor 19 in patients with bile acid diarrhoea: a prospective comparison of FGF19 serum assay and SeHCAT retention. Aliment Pharmacol Ther 2013; 38: 967-76.
17. Walters JRF, Tasleem AM, Omer OS, et al. A new mechanism for bile acid diarrhea: defective feedback inhibition of bile acid biosynthesis. Clin Gastroenterol Hepatol 2009; 7: 1189-94.
18. van Tilburg AJ, de Rooij FW, van den Berg JW, et al. Primary bile acid diarrhoea without an ileal carrier defect: quantification of active bile acid transport across the ileal brush border membrane. Gut 1991; 32: 500-3.
19. van Tilburg AJ, de Rooij FW, van den Berg JW, et al. Primary bile acid malabsorption: a pathophysiologic and clinical entity? Scand J Gastroenterol Suppl 1992; 194: 66-70.
20. Bajor A, Kilander A, Fae A, et al. Normal or increased bile acid uptake in isolated mucosa from patients with bile acid malabsorption. Eur J Gastroenterol Hepatol 2006; 18: 397-403.
21. Angelin B, Hershon KS, Brunzell JD. Bile acid metabolism in hereditary forms of hypertriglyceridemia: evidence for an increased synthesis rate in monogenic familial hypertriglyceridemia. Proc Natl Acad Sci USA 1987; 84: 5434-8.
22. Duane WC, Hartich LA, Bartman AE, et al. Diminished gene expression of ileal apical bile acid transporter explains impaired absorption of bile acid in patients with hypertriglyceridemia. J Lipid Res 2000; 41: 1384-9.
23. Van Mil SW, Milona A, Dixon PH, et al. Functional variants of the central bile acid sensor FXR identified in intrahepatic cholestasis of pregnancy. Gastroenterology 2007; 133: 507-16.
24. Attinkara R, Mwinyi J, Truninger K, et al. Association of genetic variation in the NR1H4 gene, encoding the nuclear bile acid receptor FXR, with inflammatory bowel disease. BMC Res Notes 2012; 5: 461.
25. Dawson PA, Lan T, Rao A. Bile acid transporters. J Lipid Res 2009; 50: 2340-57.
26. Rao AS, Wong BS, Camilleri M, et al. Chenodeoxycholate in females with irritable bowel syndrome-constipation: a pharmacodynamic and pharmacogenetic analysis. Gastroenterology 2010; 139: 1549-58.
27. Wong BS, Camilleri M, Carlson PJ, et al. A Klotho-beta variant mediates protein stability and associates with colon transit in irritable bowel syndrome with diarrhea. Gastroenterology 2011; 140: 1934-42.
28. Camilleri M, Shin A, Busciglio I, et al. Genetic variation in GPBAR1 predisposes to quantitative changes in colonic transit and bile acid excretion. Am J Physiol Gastrointest Liver Physiol 2014; 307: G508-16.
29. Swan C, Duroudier NP, Campbell E, et al. Identifying and testing candidate genetic polymorphisms in the irritable bowel syndrome (IBS): association with TNFSF15 and TNFalpha. Gut 2013; 62: 985-94.
30. Pattni SS, Brydon WG, Dew T, et al. Fibroblast Growth Factor 19 and 7a -hydroxy-4-cholesten-3-one in the diagnosis of patients with possible bile acid diarrhea. Clin Trans Gastroenterol 2012; 3: e18.
31. Love MW, Craddock AL, Angelin B, et al. Analysis of the ileal bile acid transporter gene, SLC10A2, in subjects with familial hypertriglyceridemia. Arterioscler Thromb Vasc Biol 2001; 21: 2039-45.
32. Nolan JD, Johnston IM, Pattni SS, et al. Diarrhea in Crohn's Disease: investigating the role of the ileal hormone Fibroblast Growth Factor 19. J Crohns Colitis 2015; 9: 125-31.
33. Makishima M, Okamoto AY, Repa JJ, et al. Identification of a nuclear receptor for bile acids. Science 1999; 284: 1362-5.
34. Parks DJ, Blanchard SG, Bledsoe RK, et al. Bile acids: natural ligands for an orphan receptor. Science 1999; 284: 1365-8.
35. Balesaria S, Pell RJ, Abbott LJ, et al. Exploring possible mechanisms for primary bile acid malabsorption: evidence for different regulation of ileal bile acid transporter transcripts in chronic diarrhoea. Eur J Gastroenterol Hepatol 2008; 20: 413-22.
36. Gadaleta RM, van Erpecum KJ, Oldenburg B, et al. Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. Gut 2011; 60: 463-72.
37. Zhou X, Cao L, Jiang C, et al. PPARalpha-UGT axis activation represses intestinal FXR-FGF15 feedback signalling and exacerbates experimental colitis. Nat Commun 2014; 5: 4573.
38. Schmidt DR, Holmstrom SR, Fon TK, et al. Regulation of bile acid synthesis by fat-soluble vitamins A and D. J Biol Chem 2010; 285: 14486-94.
39. Johnston I, Pattni SS, Nolan JD, et al. Vitamins A and D in primary bile acid diarrhea: a prospective study. Gastroenterology 2012; 142 (Suppl 1): S268-69.
40. Garcia-Rodriguez JL, Barbier-Torres L, Fernandez-Alvarez S, et al. SIRT1 controls liver regeneration by regulating bile acid metabolism through farnesoid X receptor and mammalian target of rapamycin signaling. Hepatology 2014; 59: 1972-83.
41. Kazgan N, Metukuri MR, Purushotham A, et al. Intestine-specific deletion of SIRT1 in mice impairs DCoH2-HNF-1alpha-FXR signaling and alters systemic bile acid homeostasis. Gastroenterology 2014; 146: 1006-16.
42. Vergnes L, Lee JM, Chin RG, et al. Diet1 functions in the FGF15/19 enterohepatic signaling axis to modulate bile acid and lipid levels. Cell Metab 2013; 17: 916-28.
43. Walters JR, Johnston IM, Nolan JD, et al. The response of patients with bile acid diarrhoea to the farnesoid X receptor agonist obeticholic acid. Aliment Pharmacol Ther 2015; 41: 54-64.